Oct, 13 2016 18:15 JST

Source: Eisai

Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide

Japan's First Food with Function Claims Drink Containing Ceramide
- "Drink" to Counter Dry Skin -

TOKYO, Oct, 13 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch its first food with function claims Chocola BB Rich Ceramide (Notification number: B60) in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. The product is Japan's first drink that is a type of food with function claims containing glucosylceramide derived from rice.(1)

Ceramide is a component of the stratum corneum of the epidermis layer of human skin. Normally, ceramide fills the spaces between cells in the corneum of the skin, and plays a role in restraining the loss of moisture to the outside as well as protecting the skin from external stimuli such as ultraviolet rays. Therefore, a lack of ceramide advances transpiration of skin moisture, potentially leading to dryness in the skin. Since ceramide levels decline with age, it is important to appropriate replenish ceramide to counter dryness.

Containing glucosylceramide as its active component to make it harder for moisture to escape from the skin,(2) Chocola BB Rich Ceramide is a product that you can drink to counter dry skin. Furthermore, in addition to ceramide, the drink also contains collagen and hyaluronic acid which are known for their beauty properties, and is recommended for people who are highly beauty conscious. Chocola BB Rich Ceramide has a delicious, easy to drink pear flavor, is low in calories (8.2 kcal), and with zero caffeine, can be safely consumed before sleep.

Chocola BB Rich Ceramide is now available nationwide through a wide range of retail outlets including drug stores, pharmacies, convenience stores and Eisai's internet retailing site.

Centered around the signature OTC product Chocola BB Plus (Third-class OTC drug) for the relief of skin trouble, acne and mouth ulcers, Eisai has been expanding the Chocola BB brand to suit the needs and lifestyles of its customers such as Chocola BB Royal 2 (quasi-drug), a nutritional drink for invigoration when physically fatigued, Chocola BB Joma, a soft drink that contains vitamin B6 (Food with Nutrient Function Claims), and Chocola BB Mouth Ulcer Repair Shot (Third-class OTC drug), an oral care spray launched in August.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.

(1) Chocola BB Rich Ceramide was accepted by the Consumer Affairs Agency as Japan's first food with functional claims drink that contains glucosylceramide derived from rice.

(2) For information such as the scientific basis of Chocola BB Rich Ceramide, please refer to the Consumer Affairs Agency's home page:
https://www.fld.caa.go.jp/caaks/cssc02/?recordSeq=41604270150104 (in Japanese only)


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
June 14 2018 09:11 JST
 
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA
June 13 2018 11:53 JST
 
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA
June 11 2018 11:44 JST
 
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
June 06 2018 11:16 JST
 
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
June 05 2018 09:08 JST
 
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting
June 04 2018 20:10 JST
 
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma
May 31 2018 12:33 JST
 
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018
May 28 2018 16:06 JST
 
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease
May 25 2018 14:00 JST
 
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib
May 25 2018 10:43 JST
 
More Press release >>

Latest Press Release


More Latest Release >>